Progranulin and CTRP3 in Metabolic Syndrome

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

K. M. Choi, Korea University

ClinicalTrials.gov Identifier:

NCT01668888

First received: August 14, 2012

Last updated: August 16, 2012

Last verified: August 2012

History of Changes

Purpose

Inflammation has been known to be a pivotal pathogenic mechanism of obesity-related disorders such as type 2 diabetes, metabolic syndrome and atherosclerosis. Adipose tissue functions as a major endocrine organ by adipokine mediated modulation of a number of signaling cascades in target tissues, that has pro-inflammatory or anti-inflammatory activities. Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to clarify the clinical meaning of these two adipokines in the subjects with or without metabolic syndrome

Condition
Metabolic Syndrome

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional

Resource links provided by NLM:

MedlinePlus related topics: Metabolic Syndrome

U.S. FDA Resources

Further study details as provided by Korea University:

Primary Outcome Measures:

Serum concentration of progranulin in the subjects with metabolic syndrome [ Time Frame: 12week ] [ Designated as safety issue: No ]
Serum concentration of CTRP3 in the subjects with metabolic syndrome [ Time Frame: 12week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

The relationship of serum progranulin levels with cardiovascular risk factors [ Time Frame: 12 week ] [ Designated as safety issue: No ]
The relationship of serum CTRP3 levels with cardiovascular risk factors [ Time Frame: 12 week ] [ Designated as safety issue: No ]

Enrollment:	127
Study Start Date:	May 2012
Study Completion Date:	August 2012
Primary Completion Date:	August 2012 (Final data collection date for primary outcome measure)

Groups/Cohorts
Apparently Helathy Subjects

Eligibility

Ages Eligible for Study:	20 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

The subjects who visited for a routine health check-up at the Health Promotion Center of Korea University Guro Hospital were enrolled using predefined inclusion and exclusion criteria.

Criteria

Inclusion Criteria:

20<age<80
apparently healthy subjects

Exclusion Criteria:

a history of CVD
diabetes
stage 2 hypertension
malignancy
severe renal or hepatic disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668888

Locations

Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of

Sponsors and Collaborators

Korea University

More Information

No publications provided by Korea University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Choi DS, Baik SH, Blüher M, Youn BS, Choi KM. Implication of progranulin and C1q/TNF-related protein-3 (CTRP3) on inflammation and atherosclerosis in subjects with or without metabolic syndrome. PLoS One. 2013;8(2):e55744. doi: 10.1371/journal.pone.0055744. Epub 2013 Feb 7.

Responsible Party:	K. M. Choi, Professor, Korea University
ClinicalTrials.gov Identifier:	NCT01668888 History of Changes
Other Study ID Numbers:	KoreaHealth_Progranulin
Study First Received:	August 14, 2012
Last Updated:	August 16, 2012
Health Authority:	South Korea: Institutional Review Board

Additional relevant MeSH terms:

Metabolic Syndrome X
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 16, 2013

To Top